The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death

Laleh Kamalian a,1, Amy E. Chadwick a,1,*, Mark Bayliss a, Neil S. French a, Mario Monshouwer b, Jan Snoeys b, B. Kevin Park a

a MRC Centre for Drug Safety Science, The Department of Clinical and Molecular Pharmacology, The University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
b Pharmacokinetics Dynamics and Metabolism, Janssen Research and Development, Beerse, Belgium

A B S T R A C T

Drug-induced mitochondrial dysfunction has been hypothesized to be an important determining factor in the onset of drug-induced liver injury. It is essential to develop robust screens with which to identify drug-induced mitochondrial toxicity and to dissect its role in hepatotoxicity. In this study we have characterised a mechanistically refined HepG2 model, using a panel of selected hepatotoxins and non-hepatotoxins. We have demonstrated that acute metabolic modification, via glucose-deprivation over a 4 h period immediately prior to compound addition, is sufficient to allow the identification of drugs which induce mitochondrial dysfunction, in the absence of cell death over a short exposure (2–8 h) using a plate-based screen to measure cellular ATP content and cytotoxicity. These effects were verified by measuring changes in cellular respiration, via oxygen consumption and extracellular acidification rates. Overall, these studies demonstrate the utility of HepG2 cells for the identification of mitochondrial toxins which act directly on the electron transport chain and that the dual assessment of ATP content alongside cytotoxicity provides an enhanced mechanistic understanding of the causes of toxicity.

1. Introduction

Drug-induced liver injury (DILI) is a major clinical problem. Hepatic adverse drug reactions have a global incidence of 13.9 per 100,000 inhabitants/year and over 1000 drugs are known to induce DILI. However, in many cases DILI is not predictable from the primary pharmacology of the drug, is not detected preclinically, and in most cases have no defined mechanisms (Hussaini and Farrington, 2014). Drug-induced mitochondrial dysfunction has been hypothesized to be a determining link in the onset of such idiosyncratic DILI and 50% of drugs with Black Box Warnings for DILI contain mitochondrial liabilities (Boelsterli and Lim, 2007; Labelle et al., 2008). Due to several high profile drug withdrawals and clinical trial failures, such as fialuridine and troglitazone, in which mitochondrial toxicity has been implicated it is essential to develop robust screens with which to identify the potential for mitochondrial toxicity in new chemical entities and models which can be used to link the onset of mitochondrial dysfunction with cell death and ultimately the hepatotoxic response.

Mitochondrial toxicity is difficult to model in vivo as typical inbred rodent models are young and healthy with a large respiratory capacity (Pereira et al., 2012). Hence, their efficiently functioning mitochondria can tolerate damage and toxicity is not induced. Some progress has been made in producing transgenic mice, such as SOD2(+/-), in which underlying mitochondrial stress is hypothesised to enhance sensitivity to mito-hepatotoxins (Ong et al., 2007; Ramachandran et al., 2011). Deficiencies also exist in the models of mitochondrial toxicity in vitro. In most standard preclinical models the tumour-derived cells, such as HepG2 cells, have gained the ability to vary routes of energy production allowing them to utilise glycolysis alongside oxidative phosphorylation (OXPHOS) in order to sustain continued growth in anaerobic conditions. However, this reduces their sensitivity to mitotoxicants. This area was transformed by the description of a technique to confer mitochondrial susceptibility to HepG2 cells by culturing the cells in media in

Abbreviations: ADR, adverse drug reaction; CCCP, carbonyl cyanide m-chlorophenyl hydrazine; DILI, drug-induced liver injury; ET, electron transport chain; EC50-ATP, drug concentration which decreases cellular ATP level by 50%; EC50,EC0.5 CT, drug concentration which increases cytotoxicity by 150%; ECAR, extracellular acidification rate; FHH, fresh human hepatocytes; Gal, galactose; Glu, glucose; MIP-DILI, mechanism based integrated systems for the prediction of drug-induced liver injury consortia; OCR, oxygen consumption rate.

* Corresponding author. Tel.: +44 (151) 7950148; fax: +44 (151) 7945540. E-mail address: Amy.Chadwick@liverpool.ac.uk (A.E. Chadwick).

1 These authors contributed equally to this work.
which galactose had been substituted in the place of glucose, thus blocking ATP generation via glycolysis and forcing the cells to rely upon OXPHOS for the production of ATP (Marroquin et al., 2007). Subsequently this model has been adopted by many pharmaceutical companies in order to screen for mitochondrial toxicity preclinically and several publications have detailed its relevance for the investigation of mitochondrial toxicity in several cell types (Pereira et al., 2012; Swiss et al., 2013; Will and Dykens, 2014). Indeed, a survey commissioned by the MIP-DILI (Mechanism-based Integrated systems for the Prediction of Drug-Induced Liver Injury) consortia revealed that 75% of the eight pharmaceutical companies that responded used the glucose/galactose model to screen for mitochondrial toxicity.

Funded by the European Innovative Medicines Initiative, the MIP-DILI consortia has been formed to develop and evaluate innovative mechanism-based integrated systems for the prediction of DILI with the goal of improving the tools used to test for liver toxicity during drug development. Within this framework we have performed studies to define the experimental utility of the HepG2 model against a panel of selected hepatotoxicants and mitochondrial poisons (Table 1) using a refined method with increased mechanistic specificity. Specifically, we report a method by which the metabolic switch, glucose/galactose media change, takes place over a 4 h period immediately prior to initiation of drug exposure rather than adaptation over several weeks (Fig. 1), based upon work in stem-cell derived hepatocytes and cardiomyocytes (Swiss et al., 2013). In this way it is possible to compare the absolute effects of metabolic modification on drug sensitivity in cells originating from the same source. Furthermore, most previous studies have used long exposure to hepatotoxins with an endpoint measure of cytotoxicity which does not allow examination of the role of mitochondrial dysfunction in the absence of cell death. The biological relevance of the screen was confirmed by the measurement of changes in mitochondrial respiration and glycolytic function using a Seahorse analyser. Overall, these studies confirm the utility of HepG2 cells to identify certain mitochondrial toxins, although it also highlights particular cases in which this screen is not appropriate. Additionally, these studies provide a clear mechanism, by measuring changes in cellular ATP content in the absence of cell death, with which to evaluate the role of mitochondrial dysfunction in the subsequent induction of cell death. However, our approach has exemplified the limitations of this assay both in terms of its applicability to targets within the mitochondria as well as the translatability of these in vitro screens to patients.

2. Materials and methods

2.1. Materials

All Seahorse consumables were purchased from Seahorse Biosciences (North Billerica, MA, USA). Mitochondrial ToxGlo Assay kit and the CellTiter-Glo Assay kit were purchased from Promega (Southampton, UK). Cytotoxicity Detection Kit was purchased from Roche Diagnostics Ltd (West Sussex, UK). All forms of Dulbecco’s modified media, Rat tail Collagen I and Phosphate Buffered Saline (PBS) were purchased from Life Technologies (Paisley, UK). HepG2 cells were purchased from European Collection of Cell Cultures (ECACC, Salisbury, UK). All other reagents and chemicals were purchased from Sigma Aldrich (Dorset, UK).

2.2. Cell culture

HepG2 cells were maintained in DMEM high-glucose media (glucose 25 mM) supplemented with fetal bovine serum (10% v/v), L-glutamine (2 mM), sodium pyruvate (1 mM) and HEPES (1 mM). All cells were incubated under humidified air containing 5% CO₂ at 37 °C. Cells were used up to passage 25.

2.3. Cell plating and metabolic switch

On the morning of the experiment WT HepG2 cells were collected by trypsinisation and then washed three times in either serum free glucose or galactose media (DMEM containing 25 mM glucose or 10 mM galactose, respectively, plus supplements listed above) before finally plating into a 96-well plate (12,000 cells/100 µl/well). HepG2 were then incubated (4 h, 37 °C, 5% CO₂). Drug stock solutions were made up in DMSO and the final solvent concentration was below 0.5% v/v, with a vehicle control, in each experiment.

2.4. Assessment of mitochondrial toxicity using the Mitochondrial ToxGlo Assay to quantify cellular ATP content alongside cell death

Following drug incubation (2 h) the Mitochondrial ToxGlo Assay was performed according to the manufacturers’ instructions. Briefly, cytotoxicity reagent was prepared by adding bis-AAF-R110 substrate to the assay buffer (5 µl/1 ml). 20 µl of the cytotoxicity reagent was added to each well containing 100 µl media. The plate was shaken for one minute before incubation (37 °C, 30 min). The fluorescent signal indicating dead cell protease activity was measured at 485 nm Ex/520–530 nm Em using a plate reader (Varioskan, Thermo Scientific). The plate then was left to equilibrate (room temperature, 10 min). ATPase reagent (100 µl) was added to each well, the plate was shaken (1 min) before the luminescence signal was measured using a plate reader (Varioskan, Thermo Scientific).

2.5. Assessment of cell viability using lactate dehydrogenase (LDH) content of the cells with ATP assay

Cells were plated as for the Mitochondrial ToxGlo Assay. Two plates were prepared, one plate to be used to measure the ATP level the other for LDH dehydrogenase quantification. Following drug incubation (4, 8 h) ATP content was assessed using the Promega Cell-titre glo assay according to the manufacturers’ instructions. Briefly, 30 µl of ATP reagent was added to each well containing 100 µl of media. The plate was shaken (1 min), then 100 µl of the well content was transferred to a white 96 well plate and the ATPase luminescence was measured using a plate reader (Varioskan, Thermo Scientific). The LDH content of the cells and the supernatant was measured according to the manufacturer’s instruction.

2.6. Seahorse assay

WT HepG2 cells were plated on collagen coated (50 µg/ml in 0.02 M acetic acid), XF 96-well cell culture microplates (25,000 cells/100 µl medium/well) overnight. The culture medium was removed from each well and replaced by 175 µl of unbuffered Seahorse Assy media supplemented by either 25 mM glucose or 10 mM galactose, pre-warmed to 37 °C. Cells were incubated in a CO₂ free incubator at 37 °C for 1 h. Prior to the rate measurements, the XF96 Instrument (Seahorse biosciences, North Billerica, MA) gently mixed the assay media in each well for 10 min to allow the oxygen partial pressure to reach equilibrium. The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured simultaneously three times to establish a baseline rate. For each measurement there was a 3 min mix followed by a 3 min wait time to restore normal oxygen tension and pH in the microenvironment surrounding the cells. Drug injection was only performed at the end of the basal measurement cycles, to final...
concentrations equal to the EC50-ATPgal concentration determined by Mitochondrial ToxGlo Assay for each compound. The duration of the assay was 120 min.

2.7. Statistical analysis

Values are expressed as a mean ± standard deviation (S.D.) calculated from at least three independent experiments, denoted by n number. Data was analysed using one way ANOVA or paired T-test when appropriate. All calculations were performed using StatsDirect statistical software; results were considered to be significant when P-values were less than 0.05.

3. Results and discussion

3.1. The dual assessment of cellular ATP content and cytotoxicity can identify the early onset of mitochondrial dysfunction before cell death in HepG2 cells

The effect of classic mitochondrial toxins with well-defined mitochondrial targets; rotenone, antimycin A and carbonyl cyanide

<table>
<thead>
<tr>
<th>Compound</th>
<th>Primary use</th>
<th>Clinical availability</th>
<th>Hepatotoxic?</th>
<th>Mitochondrial liability?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>Yes</td>
</tr>
<tr>
<td>Rotenone</td>
<td>Insecticide</td>
<td>N/A</td>
<td>N/A</td>
<td>Yes</td>
</tr>
<tr>
<td>CCCP</td>
<td>Weak acid</td>
<td>N/A</td>
<td>N/A</td>
<td>Yes</td>
</tr>
<tr>
<td>Antimycin-A</td>
<td>Fish poison</td>
<td>N/A</td>
<td>N/A</td>
<td>Yes</td>
</tr>
<tr>
<td>Digitonin</td>
<td>Detergent</td>
<td>N/A</td>
<td>N/A</td>
<td>No</td>
</tr>
<tr>
<td>Paracetamol</td>
<td>Pain killer</td>
<td>Available</td>
<td>Yes (mediated via reactive metabolites)</td>
<td>Yes (Kon et al., 2004; Parmar et al., 1995)</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Anti-arrhythmic</td>
<td>Black-box warming</td>
<td>Yes (Fromenty et al., 1990; Kennedy et al., 1996)</td>
<td></td>
</tr>
<tr>
<td>Busprofen</td>
<td>Anti-MCF</td>
<td>Available</td>
<td>Yes (Dykens et al., 2008)</td>
<td></td>
</tr>
<tr>
<td>Tolcapone</td>
<td>Anti</td>
<td>Available</td>
<td>Yes (Korlipara et al., 2004)</td>
<td>(Fischer et al., 2010)</td>
</tr>
<tr>
<td>Entacapone</td>
<td></td>
<td>Available</td>
<td>Yes (Fattinger et al., 2001)</td>
<td></td>
</tr>
<tr>
<td>Bosentan</td>
<td>Endothelin receptor antagonist</td>
<td>Available</td>
<td>Yes (Moreno-Sanchez et al., 1999)</td>
<td></td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Nonsteroidal anti-inflammatory drug</td>
<td>Available</td>
<td>Yes (Carvalho et al., 2008)</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>Antidiabetic</td>
<td>Available</td>
<td>No (Kennedy et al., 1996)</td>
<td></td>
</tr>
<tr>
<td>Perhexiline</td>
<td>Antianginal</td>
<td>Available</td>
<td>Yes (Kenne et al., 2008)</td>
<td></td>
</tr>
<tr>
<td>Ximelagatran via active form melagatran</td>
<td>Anticoagulant</td>
<td>Withdrawn</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Troglitazone</td>
<td>Antidiabetic</td>
<td>Withdrawn</td>
<td>Yes (Nadanaciva et al., 2007; Garcia-Ruiz et al., 2013; Scatena et al., 2004)</td>
<td></td>
</tr>
<tr>
<td>Pioglitazone</td>
<td>Available</td>
<td>No</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Non-applicable.

Fig. 1. The work flow of proposed mitochondrial toxicity screen assay (A) compared to the original strategy (B). (A) Starting with wild type HepG2 cells, cells are cultured in serum free DMEM media containing glucose (25 mM) or galactose (10 mM) for four hours at 37°C. Cells are then exposed to the serial dilutions of the tested compound for two hours. Cell membrane integrity and ATP level are measured for each compound in glucose or galactose media compared to the values measured in the vehicle control. (B) The original mitochondrial toxicity model started with two different cell lines, wild type and galactose HepG2 cell lines, and then exposed the cells to the tested compound for 24 h before cell viability was measured (ATP or MTT).
m-chlorophenyl hydrazine (CCCP) (0–100 μM), on the ATP level and membrane integrity of HepG2 cells was examined alongside digitonin, a non-mitochondria targeted cytotoxic detergent as a negative control. Mitotoxicity was defined by calculating the parameters of EC_{50}-ATP (the concentration which causes a 50% drop in ATP content) and EC_{150-CT} (the concentration which causes a 150% increase in cytotoxicity) in glucose and galactose media from dose–response curves (Fig. 2). In these experiments ATP levels measured in galactose media are correlated with mitochondrial function due to the lack of glycolytic function. After 2 h of exposure, rotenone, CCCP and antimycin A produced an EC_{50}-ATP in cells cultured in glucose-free galactose medium at significantly lower concentrations compared to those cultured in high glucose medium, when cells remained viable. A compound is defined as mitotoxic if the difference between values for EC_{50-ATPglu} and EC_{50-ATPgal}, and also the difference between EC_{50-ATPgal} and EC_{150-CTgal} were statistically significant (One Way ANOVA, p values less than 0.05) (Table 2). In most cases where there was calculated to be a significant difference, the EC_{50-ATPglu}/EC_{50-ATPgal} ratio and also the EC_{150-CTgal}/EC_{50-ATPgal} were >2, which is in line with previous publications (Swiss et al., 2013). These ratios represent different aspects of mitochondrial toxicity. An EC_{50-ATPglu}/EC_{50-ATPgal} of >2 indicates that the tested compound contains a mitochondrial liability and thus has a more significant effect in galactose media due to the absence of glycolysis. An EC_{150-CTgal}/EC_{50-ATPgal} of >2 is indicative of mitochondrial dysfunction preceding cell death.

3.2. The acute HepG2 metabolic model can identify drugs which induce toxicity via mitochondrial dysfunction

3.2.1. Standard two hours exposure to limited concentrations of the compounds

The assay was next performed using a panel of compounds, selected by MIP-DILI as training compounds (Table 1). In the

![Fig. 2. The effect of rotenone, antimycin A, CCCP and digitonin exposure on ATP levels and cytotoxicity of HepG2 cells (2 h) compared to the vehicle control. Serial concentrations of the compounds were used up to 100 μM in glucose or galactose serum free media. The values are expressed as percentage of those of the vehicle control.](image)

**Table 2** Compounds found to be positive for mitotoxicity, alongside control compounds, following 2 h exposure in HepG2 cells.

<table>
<thead>
<tr>
<th>Compound</th>
<th>EC_{50-ATP} (μM) ± S.D.</th>
<th>EC_{150-CT} (μM) ± S.D.</th>
<th>EC_{50-ATPglu}/EC_{50-ATPgal} (p value)</th>
<th>EC_{150-CTgal}/EC_{50-ATPgal} (p value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotenone</td>
<td>&gt;100</td>
<td>0.05 ± 0.04</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Antimycin A</td>
<td>&gt;100</td>
<td>0.003 ± 0.001</td>
<td>&gt;100</td>
<td>49 ± 2</td>
</tr>
<tr>
<td>CCCP</td>
<td>&gt;100</td>
<td>0.90 ± 0.90</td>
<td>&gt;100</td>
<td>&gt;100</td>
</tr>
<tr>
<td>Digitonin</td>
<td>2.8 ± 1.7</td>
<td>2.1 ± 1.5</td>
<td>2.7 ± 1.5</td>
<td>2.7 ± 2.3</td>
</tr>
<tr>
<td>MIP-DILI training compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amiodarone</td>
<td>&gt;300</td>
<td>158 ± 30</td>
<td>&gt;300</td>
<td>196 ± 5</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>39 ± 3</td>
<td>17 ± 5</td>
<td>76 ± 7</td>
<td>142 ± 59</td>
</tr>
<tr>
<td>Troglitazone</td>
<td>81 ± 42</td>
<td>28 ± 8</td>
<td>&gt;300</td>
<td>84 ± 24</td>
</tr>
<tr>
<td>Tolcapone</td>
<td>&gt;300</td>
<td>53 ± 4</td>
<td>&gt;300</td>
<td>&gt;300</td>
</tr>
<tr>
<td>Buspirone</td>
<td>&gt;900</td>
<td>338 ± 105</td>
<td>&gt;900</td>
<td>&gt;900</td>
</tr>
</tbody>
</table>

The results are quoted ± standard deviation (n = 3). Key: a – cytotoxicity; P value indicates the significance of EC_{50-ATPglu} compared with EC_{50-ATPgal} and P value indicates the significance of EC_{150-CTgal} compared with EC_{50-ATPgal} as tested by ANOVA.
standard assay cells were exposed to drugs (0–300 µM) for 2 h (Fig. 3). Four of the fourteen compounds tested; nefazodone, troglitazone, amiodarone and tolcapone could be classified as containing a mitochondrial liability (based upon the EC50-ATPglu vs EC50-ATPgal) and that mitochondrial dysfunction preceded cell death (based upon the EC50-ATP gal vs EC150-CT gal), as defined above (Fig. 3A and Table 2). Buspirone could also be classified as mitotoxic when an extended concentration range was used.

**Fig. 3.** The effect of MIP-DILI training compounds on ATP and cytotoxicity of HepG2 cells (2 h) compared to the vehicle control. Serial concentrations of the compounds were used up to 300 µM (or 900 µM for buspirone) in glucose or galactose serum free media. (A) Compounds that were labelled as having a mitochondrial liability (EC50-ATPgal/EC50-ATPglu of >2) and in which mitochondrial dysfunction precedes cell death (EC150-CTgal/EC50-ATPgal of >2). (B) Compounds which did not change the ATP or cytotoxicity level significantly throughout the 2 h assay duration. (C) Compounds which were negative for mitochondrial toxicity (EC50-ATPgal/EC50-ATPglu and EC150-CTgal/EC50-ATPgal equal to 1). Key: ATP and cytotoxicity levels are reported as the percentage of the vehicle control ± S.D. (n = 3).
These five compounds have all previously been cited as causing mitochondrial dysfunction predominantly via some effect on the electron transport chain (Table 1).

Over 2 h seven compounds; diclofenac, bosentan, paracetamol, metformin, pioglitazone, entacapone and ximelagatran were seen to induce concentration-dependent increases in cellular ATP content in both glucose and galactose medium in the absence of cytotoxicity (Fig. 3B). This increase was most prominent for diclofenac and bosentan (up to 140% of vehicle only). This phenomenon has been reported previously for drugs such as valinomycin (Lofrumento et al., 2011). We hypothesise that this increase may form part of a protective mechanism and the activation of cellular defence. For example, cells may either up-regulate ATP synthesis or switch off ATP consuming processes in order to increase and/or maintain ATP for processes such as glutathione synthesis or apoptotic cell death. These compounds were therefore subject to further testing at extended concentrations; 30 mM, 10 mM, 3 mM and 1 mM for paracetamol, metformin and diclofenac respectively and 2.7 mM for pioglitazone and entacapone (2 h). However, this did not lead to the classification of any of these compounds as either positive or negative for mitochondrial toxicity (data not shown).

Surprisingly, the action of perhexiline, a known inhibitor of fatty acid oxidation, closely resembled digitonin and induced cell death in tandem with decreases in ATP levels (Fig. 3C). This finding may result from the action of perhexiline as an inhibitor of fatty acid oxidation via its inhibition of CPT-1, a carnitine transporter (Kennedy et al., 1996). The compound etomoxir has been shown to use this mechanism to induce both a decrease in OXPHOS without a substantial increase in glycolysis, alongside a significant cytotoxic effect due to the generation of reactive oxygen species (Pike et al., 2011). This may explain the findings here of a decrease in ATP occurring in both media alongside the induction of cell death. Therefore, this assay incorrectly defines perhexiline as negative for mitochondrial toxicity, thus exemplifying that this short assay cannot identify all forms of mitochondrial dysfunction.
3.2.2. Extended exposure to high concentrations of the compounds

Several of the compounds which remained unclassified in the 2 h assay are known inducers of mitochondrial dysfunction (Table 1) and so we investigated whether this discrepancy was due to the acute exposure by using an extended concentration range and time course (4 or 8 h) for the remaining compounds, except for bosentan, as it induces cholestatic injury which would not be evident in unpolarised HepG2 cells (Fattinger et al., 2001). Monitoring baseline cell health revealed that the method of acute glucose starvation could only be reliably used up to 8 h and that LDH is a more sensitive and reproducible cell death marker than the cell death protease included in the Mitochondrial ToxGlo Assay at these extended timepoints (data not shown). In this way we defined the shortest duration, with the lowest concentration of drug, at which a differential effect upon ATP content was observed in the two media in the absence of cell death (Fig. 4).

Using this classification system, five of the seven tested compounds, paracetamol, metformin, pioglitazone, diclofenac and entacapone, could be classified as weak mitochondrial toxins in accordance with the literature, in which each of these compounds has been described to have a mitochondrial liability via the ETC (Table 1). However, in the case of entacapone and pioglitazone this liability is substantially weaker than their structurally related, more hepatotoxic counterparts, tolcapone and troglitazone and exemplifies the power of this assay in detecting the weakest mitochondrial toxins and to rank compounds in terms of potency of mitotoxicity. This is a clear advantage of this model system. In each case of related compounds studied here, nefazodone and buspirone; tolcapone and entacapone and troglitazone and pioglitazone the striking difference in potency of mitochondrial dysfunction can be correlated with clinical hepatotoxic potential. Specifically, entacapone, pioglitazone and buspirone are clinically useful drugs with low rates of hepatotoxicity, in contrast to their pairs, all of which have been withdrawn, discontinued during development or have a black-box warning for hepatotoxicity. Moreover, although we have correctly identified the weak mitochondrial liability within metformin it is not classified as a clinical hepatotoxin (Table 1).

Paracetamol was unexpectedly observed to induce mitochondrial dysfunction after 4 h, but only at a high concentration (30 mM). Although paracetamol is reported to target the mitochondria, toxicity is mediated via CYP P450 mediated reactive metabolites, especially the quinoneimine (Nelson, 1990). As it is known that levels of many CYP enzyme isoforms are low in HepG2 cells (Gerets et al., 2012) we carried out HPLC-MS/MS analysis to measure the concentrations of metabolites produced by the cells (data not shown). This revealed that the key reactive metabolites were present only in very low levels, close to or below the limit of detection. This correlates with iTRAQ analysis of the HepG2 proteome (data not shown, to be published elsewhere) which indicates the overall level of drug metabolising enzymes in HepG2 cells to be less than approximately 1% of those found in fresh human hepatocytes. Therefore, it is unlikely that the toxicity observed in these studies is related to the usual mechanism of paracetamol toxicity via the formation of reactive metabolites.

Ximelagatran was negative as a mitotoxin throughout these experiments which was anticipated (Kenne et al., 2008). However, Ximelagatran is a pro-drug; the active component, melagatran, is formed via two intermediate metabolites (hydroxyl melagatran and ethyl-melagatran) with formation mediated via non-CYP P450 enzyme systems (Clement and Lopian, 2003; Eriksson et al., 2003). Therefore it was considered important to determine whether the active metabolite was produced in the model systems utilised here. HPLC-MS/MS analysis detected insignificant levels of melagatran and the two intermediate metabolites (data not shown) and hence it is not possible to unequivocally rule out mitochondrial toxicity induced by metabolism of Ximelagatran using this assay.

Fig. 5. Oxygen consumption rate (OCR) and extra cellular acidification rate (ECAR) in HepG2 cells in response to drug exposure. (A) and (B) Shift in the bioenergetic profile of HepG2 cells as a result of exposure to rotenone or CCCP at 29 min in glucose and galactose media. (C) and (D) Percent fold change of OCR and ECAR to the basal measurement after 29 and 120 min exposure to rotenone, CCCP, amidarone, tolcapone, troglitazone, buspirone, nefazodone, ximelagatran and vehicle control (0.5% DMSO) in glucose media, at the concentrations determined by mito-tox assay (EC50-ATPgal). Results are reported as the percentage fold change compared to the basal level ± S.D. (n = 3). P < 0.05, **P < 0.01, ***P < 0.001 significance of data treated with compound compared to basal respiration (A and B) or compared to vehicle control (C and D), as tested by ANOVA.
3.3. ATP/cytotoxicity assessment in HepG2 cells reflects the effects of the compounds upon cellular respiration

In order to confirm that the ATP measurements are representative of the functional effects on the mitochondria, Seahorse technology was used to define the bioenergetic phenotype of the cells cultured with and in the absence of glucose and to determine how this affects their response to mitochondrial toxicants. Cells in both conditions had similar basal phenotypes in terms of OCR (indicative of OXPHOS rates) and ECAR (indicative of glycolysis rates) with differences only becoming apparent once cells were exposed to mitochondrial toxins (Fig. 5). Although rotenone induced a similar decrease in OCR in both media at 29 min, only in glucose media is this accompanied by a significant increase in ECAR (Fig. 5A). In response to CCCP, OCR was only significantly increased in galactose whilst ECAR was only significantly increased in glucose media (Fig. 5B). In each case the significant increase in ECAR is only measured when cells are cultured in the presence of glucose as this allows the compensatory increase in glycolysis thus demonstrating the metabolic mechanisms underlying the acute glucose deprivation screen for mitochondrial damage.

Using this protocol to measure respiration in glucose media troglitazone, nefazodone, buspirone and amiodarone were seen to behave in a fashion similar to rotenone; decreasing OCR with a concomitant increase in ECAR (Fig. 5C and D), indicative of their ability to induce mitochondrial dysfunction via inhibition of the electron transport chain (Table 1). The compounds generated similar results in galactose media (data not shown). Interestingly, amiodarone and tolcapone did not increase OCR, as would be expected, due to their reported action as uncouplers of respiration. Further work revealed that this discrepancy was not concentration related (data not shown). However, amiodarone has been described to have pleiotropic effects on the mitochondria; it is an uncoupler and also an inhibitor of the electron transport chain and β-oxidation, and this may underlie this result (Fromenty et al., 1990; Kennedy et al., 1996). Moreover, tolcapone has been identified as an uncoupler and inhibitor of several complexes of the electron transport chain (Table 1). These results suggest that bioenergetic profile patterns are compound dependent and that the mitotoxicity screen may be more sensitive at defining mitotoxicity via ETC dysfunction than screening basal OCR and ECAR. However, Seahorse technology may be important when conducting further in-depth mechanistic investigations of the cause of mitotoxicity.

4. Conclusion

HepG2 cells are used extensively as a preclinical model during pharmaceutical drug discovery and development despite their lack of xenobiotic metabolic capacity, altered bioenergetic phenotype and lack of polarisation. Therefore, it is often postulated that HepG2 cells are of limited relevance to clinical hepatotoxicity. However, in terms of detecting mitochondrial toxicity we postulate that the tumorigenic bioenergetic phenotype of HepG2 cells is an advantage over fresh human hepatocytes (FHH). Specifically, the Warburg effect, which confers tumorigenic cells with the ability to utilise glycolysis as an additional mechanism to produce ATP when needed, does not occur in primary hepatocytes (Warburg, 1956). Therefore, although FHH are able to detect cell toxicity/death caused via mitochondrial dysfunction, their fixed bioenergetic phenotype means that they lack the advantage of HepG2 cells in determining mechanistically whether cytotoxicity arises due to mitochondrial dysfunction as the glucose/galactose switch cannot be applied.

Overall, we have demonstrated that HepG2 cells acutely deprived of glucose are a suitable model for the identification of mitochondrial toxicity when used alongside HepG2 cells in the presence of glucose. Furthermore, the dual assessment of ATP content alongside cytotoxicity provides an enhanced mechanistic understanding of the causes of toxicity. Importantly, in this way ATP is a functional endpoint indicative of mitochondrial respiration which is sensitive enough to be measured early in toxicity, in the absence of cell death. This has allowed the identification of the time-dose window of the onset of mitochondrial dysfunction enabling the delineation of ensuing changes in cellular function to be assessed in a cause and effect manner. The utility of this assay to identify compounds which induce dysfunction of the ETC directly has been proven, with zero to low levels of false positive results. However, the use of a panel of hepatotoxins has also highlighted limitations of the screen in detecting alternative mechanisms of mitochondrial dysfunction or mitotoxicity induced via reactive metabolites or fatty acid oxidation. The functional model developed here is able to give information on the potency of a series of compounds upon mitochondrial dysfunction which may be indicative of the propensity to cause hepatotoxicity. However, it cannot be used to replace the current preclinical testing strategies to predict compounds which will induce hepatotoxicity, as there is no clear link between the concentrations which cause mitochondrial dysfunction and peak plasma concentration in humans. Therefore we propose that this updated method provides a sensitive, convenient, cost effective and fast first tier screening platform to identify mitochondrial liabilities during drug development which should be used for parent compound alongside synthetic equivalents of any significant human drug metabolites. However, we emphasise that despite the very low false positive rate of this method, the compounds identified as negative by this model should go through further cytotoxicity assessment in order to rule out their cyto- or hepato-toxicity. This method therefore provides a starting point from which to conduct further studies delineating the mechanistic pathways linking mitochondrial toxicity with the onset of DILI.

Conflict of Interests

Dr. Mario Monshouwer and Dr. Jan Snoeys are employed by Janssen Pharmaceutica and hold stock in Johnson & Johnson.

Transparency Document

The Transparency document associated with this article can be found in the online version.

Acknowledgments

This work is supported by the European Community under the Innovative Medicines Initiative (IMI) Programme through [Grant Agreement Number 115336 (MIPI-DILI)] and Janssen Pharmaceutica N.V. [Agreement ICD #387882], as part of the Drug Safety Centre supported by the Medical Research Council, United Kingdom [Grant Number G0700654] to [LK].

References


